Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.96+0.01 (+1.44%)
Close on Nov 17, 2026Market cap $26.64MP/E –Yield –
Earnings
Inmune Bio's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q2 FY2025
–
EPS, Q2 FY2025
-$1.05
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Inmune Bio's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q3 FY2025ended Sep 30, 2025 | Oct 30, 2025during market hours | – | – | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 7, 2025during market hours | – | – | -$1.05 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | $50.00K | – | -$0.43 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 27, 2025during market hours | – | – | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 1, 2024during market hours | – | – | -$0.60 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 2, 2024during market hours | – | – | – | Release |
| Q1 FY2024ended Mar 31, 2024 | May 13, 2024during market hours | – | – | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 29, 2024during market hours | – | – | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 1, 2023during market hours | $43.00K | -56.1% | -$0.48 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023during market hours | $46.00K | +187.5% | -$0.36 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 4, 2023during market hours | $38.00K | -81.0% | -$0.36 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 3, 2023during market hours | – | – | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 2, 2022during market hours | $98.00K | +600.0% | -$0.43 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 4, 2022during market hours | $16.00K | – | -$0.38 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 6, 2022before the open | $200.00K | – | -$0.39 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 4, 2022during market hours | – | – | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 4, 2021during market hours | $14.00K | – | -$0.55 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 6, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 5, 2021during market hours | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 6, 2020before the open | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 6, 2020during market hours | – | – | – | Filing |
| Q1 FY2020ended Mar 31, 2020 | May 15, 2020before the open | – | – | – | Filing |
| Q4 FY2019ended Dec 31, 2019 | Mar 12, 2020during market hours | – | – | – | Filing |
| Q3 FY2019ended Sep 30, 2019 | Nov 12, 2019during market hours | – | – | – | Filing |
| Q2 FY2019ended Jun 30, 2019 | Aug 13, 2019during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Inmune Bio has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Inmune Bio puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Inmune Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- Update
- News
- News
- News
- News
- News
- Update
- Update
- News
- News
- Update
- Update
See a number that looks wrong?